COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic.
Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …